Skip to main content
Premium Trial:

Request an Annual Quote

Right at Home

An at-home, over-the-counter test for SARS-CoV-2 has received an Emergency Use Authorization from the US Food and Drug Administration, as 360Dx reports. It adds that this is the first at-home test for SARS-CoV-2 to receive an EUA that doesn't require a prescription.

The test from the Australian diagnostics firm Ellume is a rapid, lateral flow antigen test that uses a nasal swab and a smartphone app to deliver results. According to the FDA, the test identified 96 percent of positive samples and all negative samples in individuals with symptoms and, among those without symptoms, identified 91 percent of positive samples and 96 percent of negative samples.

The Washington Post adds that the test will cost about $30 and could help the US in its fight against COVID-19. "It's a big deal, and a huge step for efforts to take back control from the virus," Mara Aspinall, a biomedical diagnostics professor at Arizona State University, tells it.

Ellume says it will begin shipping tests at the beginning of January, according to the Post.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.